|
|
11021 Roselle St., Suite 100
San Diego, CA 92121 USA
phone:858-455-6006
fax:858-812-0541
|
|
| Symbol |
TEAR |
| Exchange |
Nasdaq |
| Founded |
2003 |
| Employees |
15 |
|
|
| www.tearlab.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Point of care diagnostics for ocular diseases |
|
| Management |
| Elias Vamvakas, Chief Executive Officer; Michael A. Lemp, M.D., F.A.C.S., Chief Medical Officer; Benjamin Sullivan, Ph.D., Chief Scientific Officer; Bob Walder, PA-C, Vice President, Operations; Michael Berg, Vice President Clinical & Regulatory; Steve Zmina, Vice President Manufacturing & Engineering; Tracy Puckett, Vice President Marketing |
| |
|
|
|
|
|
|
|
| Keywords |
| ophthalmology, eye, vision, eye disease, dry eye, diagnostic, lab-on-a-chip, |
|
|
|
| Description |
|
TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. |
|
| Products / Services |
The TearLab(TM) Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention.
|
|
| Technology / Differentiation |
TearLab Corporation's core technology is rooted in nanofluidics and electrochemical detection. The Company owns or has exclusively licensed numerous issued and pending patent applications that broadly cover an integrated system of tear collection and biomarker analysis.
TearLab requires only nanoliters of tear film, therefore sampling time is reduced to less than a second and the risk of reflex tearing is greatly mitigated. At the core of TearLab is a disposable lab-on-a-chip that functions as both a tear collection device and a measurement system. Consequently, tears are collected directly from the eye, eliminating the need for a standard glass capillary tube, and embedded nanofluidic channels move the tear sample to the measuring electrodes.
This patented tear collection interface effectively addresses the potential adverse effects of sample evaporation and also establishes a very simple user interface. A desktop instrument converts the electrical signals generated from the lab card into a quantitative measurement and displays it to the user. This entire workflow, from sample to result, requires less than 30 seconds. |
|
| Market / Customers |
Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley's Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide.
|
|
| Status |
| Headquartered in San Diego, CA and with offices in Milton, Ontario and Alpharetta, GA, TearLab Corporation's common shares trade on the NASDAQ Global Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. TearLab received the CE Mark for its TearLabTM Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members